Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.48), $0.07 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.69 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.